دورية أكاديمية
BMI changes in pediatric type 1 narcolepsy under sodium oxybate treatment
| العنوان: | BMI changes in pediatric type 1 narcolepsy under sodium oxybate treatment |
|---|---|
| المؤلفون: | Ponziani V., Pizza F., Zenesini C., Vignatelli L., Pession A., Plazzi G. |
| المساهمون: | Ponziani V., Pizza F., Zenesini C., Vignatelli L., Pession A., Plazzi G. |
| سنة النشر: | 2021 |
| المجموعة: | IRIS Università degli Studi di Bologna (CRIS - Current Research Information System) |
| مصطلحات موضوعية: | childhood type 1 narcolepsy, obesity, sodium oxybate, Body Mass Index, Child, Human, Overweight, Retrospective Studie, Narcolepsy |
| الوصف: | Pediatric type 1 narcolepsy (NT1) is often associated with overweight and obesity. Sodium oxybate (SO), approved for the treatment of narcolepsy with cataplexy from the age of 7 years old in the United States, has been associated with weight loss, although longitudinal pediatric studies are lacking. We report a retrospective cohort of 129 consecutive patients with a 4-year follow-up, to analyze the impact of different pharmacological treatments on body mass index (BMI) z-score. At baseline, the prevalence of obesity and overweight was 26.4% (34/129) and 29.5% (38/129), respectively. Patients were divided into three groups: Children treated with SO alone (group 1), with SO-combined therapy (group 2), and without SO (group 3). At the end of the first year of follow-up, group 1 and group 2 showed a significant BMI z-score reduction compared to baseline: From 1.2 ± 1.1 to 0.4 ± 1.4 for group 1 (p < 0.001), and from 1.4 ± 1.1 to 1 ± 1.3 for group 2 (p = 0.002), independently from baseline clinical features. In the second year, only group 2 experienced a further and significant BMI z-score decrease (from 1.0 ± 1.2 to 0.6 ± 1.2, p = 0.037). No further significant BMI z-score changes were observed in SO-treated patients in the following years. Instead, children treated without SO developed a significant weight increase between the second and third year of therapy (BMI z-score from 0.3 ± 0.9 to 0.5 ± 0.9). In conclusion, SO treatment in pediatric NT1 is associated with a favorable weight reduction in the first year of treatment. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | STAMPA |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/33388769; info:eu-repo/semantics/altIdentifier/wos/WOS:000685221400001; volume:44; issue:7; firstpage:1; lastpage:7; numberofpages:7; journal:SLEEP; http://hdl.handle.net/11585/859695Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85102501468 |
| DOI: | 10.1093/sleep/zsaa295 |
| الإتاحة: | https://doi.org/10.1093/sleep/zsaa295Test http://hdl.handle.net/11585/859695Test |
| رقم الانضمام: | edsbas.4199DD4F |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/sleep/zsaa295 |
|---|